{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:37:28Z","timestamp":1791398248327,"version":"4.3.3"},"reference-count":47,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Cycle"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.4161\/cc.11.5.19519","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T18:13:45Z","timestamp":1331057625000},"page":"1029-1039","source":"Crossref","is-referenced-by-count":30,"title":["Antitumor activity of new pyrazolo[3,4-<i>d<\/i>]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition"],"prefix":"10.1080","volume":"11","author":[{"given":"Martina","family":"Cozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pentimalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Maria","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Schenone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"D\u2019Urso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Indovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,10,28]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/path.2807","article-title":"The molecular background of aggressive B cell lymphomas as a basis for targeted therapy","volume":"223","author":"de Jong","year":"2011","journal-title":"J Pathol"},{"key":"R2","unstructured":"Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW eds. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue. Volume 2, 4th edition. Lyon, France. 2008; 262-264."},{"key":"R3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"R4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1634\/theoncologist.11-4-375","article-title":"Burkitt\u2019s lymphoma: clinicopathologic features and differential diagnosis","volume":"11","author":"Ferry","year":"2006","journal-title":"Oncologist"},{"key":"R5","first-page":"e2009030","article-title":"Clinical aspects and therapy of sporadic burkitt lymphoma","volume":"1","author":"Pagano","year":"2009","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/leu.2010.261","article-title":"Selective killing of Burkitt\u2019s lymphoma cells by mBAFF-targeted delivery of PinX1","volume":"25","author":"Zhang","year":"2011","journal-title":"Leukemia"},{"key":"R7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1044-579X(02)00058-5","article-title":"Role of genetic and epigenetic changes in Burkitt lymphoma","volume":"12","author":"Lindstr\u00f6m","year":"2002","journal-title":"Semin Cancer Biol"},{"key":"R8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/leu.2008.163","article-title":"Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib","volume":"22","author":"Yang","year":"2008","journal-title":"Leukemia"},{"key":"R10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1476-4598-8-132","article-title":"Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth","volume":"8","author":"Ke","year":"2009","journal-title":"Mol Cancer"},{"key":"R11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.leukres.2009.08.030","article-title":"Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma","volume":"34","author":"Hollmann","year":"2010","journal-title":"Leuk Res"},{"key":"R12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1517\/13543784.2010.499898","article-title":"Novel dual Src\/Abl inhibitors for hematologic and solid malignancies","volume":"19","author":"Schenone","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D et al. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization. Oncogene 2011; e-pub ahead of print 25 Jul 2011.","DOI":"10.1038\/onc.2011.286"},{"key":"R14","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-06-3469","article-title":"Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival","volume":"67","author":"Shor","year":"2007","journal-title":"Cancer Res"},{"key":"R15","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1210\/jc.2008-2511","article-title":"Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer","volume":"94","author":"Schweppe","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R16","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/sj.emboj.7601085","article-title":"Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression","volume":"25","author":"Cursi","year":"2006","journal-title":"EMBO J"},{"key":"R17","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1038\/sj.onc.1202835","article-title":"Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors","volume":"18","author":"Karni","year":"1999","journal-title":"Oncogene"},{"key":"R18","doi-asserted-by":"crossref","first-page":"19112","DOI":"10.1074\/jbc.M709882200","article-title":"SRC directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis","volume":"283","author":"Yamaguchi","year":"2008","journal-title":"J Biol Chem"},{"key":"R19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0955-0674(90)90018-A","article-title":"Control of M-phase by maturation-promoting factor","volume":"2","author":"Dor\u00e9e","year":"1990","journal-title":"Curr Opin Cell Biol"},{"key":"R20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/emboj\/16.3.545","article-title":"Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation","volume":"16","author":"O\u2019Connell","year":"1997","journal-title":"EMBO J"},{"key":"R21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1747-1028-2-12","article-title":"Cdc25 and Wee1: analogous opposites?","volume":"2","author":"Perry","year":"2007","journal-title":"Cell Div"},{"key":"R22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"R23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2008-02-137737","article-title":"AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines","volume":"113","author":"Levy","year":"2009","journal-title":"Blood"},{"key":"R24","doi-asserted-by":"crossref","first-page":"31858","DOI":"10.1074\/jbc.C100271200","article-title":"Regulation of Akt\/PKB activation by tyrosine phosphorylation","volume":"276","author":"Chen","year":"2001","journal-title":"J Biol Chem"},{"key":"R25","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1128\/MCB.25.13.5725-5737.2005","article-title":"Akt\/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2\/M transition","volume":"25","author":"Katayama","year":"2005","journal-title":"Mol Cell Biol"},{"key":"R26","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1073\/pnas.0307700101","article-title":"M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP","volume":"101","author":"Watanabe","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrc1296","article-title":"Targeting the checkpoint kinases: chemosensitization versus chemoprotection","volume":"4","author":"Zhou","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1535-7163.513.3.4","article-title":"G2 checkpoint abrogators as anticancer drugs","volume":"3","author":"Kawabe","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"R29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/carcin\/bgl214","article-title":"p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?","volume":"28","author":"Levesque","year":"2007","journal-title":"Carcinogenesis"},{"key":"R30","first-page":"8211","article-title":"Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator","volume":"61","author":"Wang","year":"2001","journal-title":"Cancer Res"},{"key":"R31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4161\/cbt.3.3.697","article-title":"Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis","volume":"3","author":"Wang","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"R32","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Hirai","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"Hirai","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"R34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"R35","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1158\/0008-5472.CAN-07-2661","article-title":"AXL is a potential target for therapeutic intervention in breast cancer progression","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res"},{"key":"R36","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.bmcl.2004.03.013","article-title":"New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation","volume":"14","author":"Schenone","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"R37","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1021\/jm050603r","article-title":"Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation","volume":"49","author":"Carraro","year":"2006","journal-title":"J Med Chem"},{"key":"R38","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1096\/fj.07-9873com","article-title":"Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells","volume":"22","author":"Spreafico","year":"2008","journal-title":"FASEB J"},{"key":"R39","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1126\/science.7545311","article-title":"Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division","volume":"269","author":"Roche","year":"1995","journal-title":"Science"},{"key":"R40","first-page":"6145","article-title":"Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest","volume":"59","author":"Moasser","year":"1999","journal-title":"Cancer Res"},{"key":"R41","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1096\/fj.09-148593","article-title":"New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells","volume":"24","author":"Rossi","year":"2010","journal-title":"FASEB J"},{"key":"R42","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/sj.cdd.4401130","article-title":"Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe","volume":"9","author":"Castedo","year":"2002","journal-title":"Cell Death Differ"},{"key":"R43","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1073\/pnas.89.7.3093","article-title":"Coordinated synthesis and degradation of cdc2 in the mammalian cell cycle","volume":"89","author":"Welch","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R44","first-page":"2161","article-title":"p53 mutations in Raji cells: characterization and localization relative to other Burkitt\u2019s lymphomas","volume":"7","author":"Duthu","year":"1992","journal-title":"Oncogene"},{"key":"R45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.cgt.7700323","article-title":"Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells","volume":"8","author":"Buttgereit","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"R46","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/j.ejmech.2008.01.034","article-title":"Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines","volume":"43","author":"Schenone","year":"2008","journal-title":"Eur J Med Chem"},{"key":"R47","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/nar\/11.5.1475","article-title":"Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei","volume":"11","author":"Dignam","year":"1983","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Cycle"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/cc.11.5.19519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T23:09:16Z","timestamp":1687302556000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/cc.11.5.19519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,10,28]]},"published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.4161\/cc.11.5.19519"],"URL":"https:\/\/doi.org\/10.4161\/cc.11.5.19519","relation":{},"ISSN":["1538-4101","1551-4005"],"issn-type":[{"value":"1538-4101","type":"print"},{"value":"1551-4005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}